AI
Wednesday, October 14, 2009 11:08:11 PM
A lot of hiring occurring at Peregrine/Avid.
$60 million dollars is currently being spent by Peregrine and its collaborators to evaluate the potential of the company's PS-targeting platform in a wide range of viral infections.
The US government, through DTRA/TMTI, has dedicated up to $44.4 million dollars just for the viral hemorrhagic fever diseases. That money has only just started flowing to these anti-viral studies.
The current $60 million dollars that is powering these studies is obviously coming from other sources, as well. We know that the Gates Foundation is behind the Peregrine mAbs that are being tested for the purpose of developing a topical microbicide to protect against HIV.
Yes, Peregrine has an anti-viral mAb that can devastate HIV. It’s called PGN632 or 11.31. At the smallest dose 11.31 almost immediately starts killing, basically 100% of the HIV virons. I’ll attach a panel graph that show just how deadly this mAb is against HIV. This work was conducted by David Montefiori at Duke.
The Gates Foundation along with the US government agency, the National Institute of Allergy and Infectious Diseases, (NIAID) are funding this HIV work.
The government of Brazil has funded a study of PS in cancer and infectious diseases. Brazil is currently running a study of our anti-PS mAbs against Leishmania.
Money is pouring into Peregrine from a number of sources, academic, private foundational and government.
The extensive current hiring is a leading indicator that the Peregrine program is about to expand, Avid, alone, is hiring 19 new employees and has taken on expanded top management: Truc Le and Chris Eso. This tells us that something very big is happening at Avid. Avid is a production facility. Avid is growing. What is going to be produced? I think it will be a large government contract through DTRA/TMTI. This will be separate from the current $44 million dollar contract. It will be a procurement contract for a stockpile of a fully human bavi mAb to protect against viral hemorrhagic fever diseases. Bavi is a broad spectrum anti-viral that can treat the wide variety of enveloped viruses. They include many of the most dangerous diseases out there.
The hiring, especially at Avid, tells me that there is going to be a large and imminent expansion at Avid. Over the mid term expect the announcement of an early approval (EUA) of a fully human bavi mAb by DTRA/TMTI and FDA. Then expect announcement of a very large stockpile procurement order at Avid for the mAb.
I think a large procurement stockpile order to Avid will go a long way in supporting the phase 3 cancer trial(s). Peregrine has many options.
On a separate note, I, personally, have voted to support Peregrine. I own a share of this company, and I will support management going forward. It is an absolute myth that management has not performed superbly; they have made major pre-clinical and clinical progress. The major support that is coming from academia, a major private foundation and governments should inform shareholders that this is an up and coming company with transformational medical technology. Supporting your company is in your interest.
The incessant bashing from some semi-literate individuals working out of cardboard cubicles should not be heeded. It’s problematic to say, exactly, who they are, or who they are employed by, but the fact that they snipe at Peregrine all day every day tells you that they have an economic interest in suppressing the price. Their day-long efforts to instill fear and doubt to produce sellers, tells you their general motivation. Because they remain here, constantly, they’re compensated. The only sane reason to suppress a price is to buy the commodity. Roundabout, they, and their employers want to buy Peregrine. Keep that thought firmly in mind. Big Pharmas will eventually buy; they just don’t want to pay the full price. Too bad, I’m holding for the much better price.
In my opinion, long investors should support this company by voting their proxy sooner rather than later, so we can move to a new price structure that satisfies NASDAQ requirements and accommodates institutional investors that are limited to prices above certain limits. I want these investors to be able to start buying and having the price supported by their buying volume.
I would like to see Peregrine releasing the bulk of their anti-viral and anti-cancer results to a clientele that includes large investors that are not eligible to buy at these current prices.
sunstar
Here is the panel of graphs that show the deadly power of Peregrine’s anti-HIV mAb, PGN632: 11.31:
$60 million dollars is currently being spent by Peregrine and its collaborators to evaluate the potential of the company's PS-targeting platform in a wide range of viral infections.
The US government, through DTRA/TMTI, has dedicated up to $44.4 million dollars just for the viral hemorrhagic fever diseases. That money has only just started flowing to these anti-viral studies.
The current $60 million dollars that is powering these studies is obviously coming from other sources, as well. We know that the Gates Foundation is behind the Peregrine mAbs that are being tested for the purpose of developing a topical microbicide to protect against HIV.
Yes, Peregrine has an anti-viral mAb that can devastate HIV. It’s called PGN632 or 11.31. At the smallest dose 11.31 almost immediately starts killing, basically 100% of the HIV virons. I’ll attach a panel graph that show just how deadly this mAb is against HIV. This work was conducted by David Montefiori at Duke.
The Gates Foundation along with the US government agency, the National Institute of Allergy and Infectious Diseases, (NIAID) are funding this HIV work.
The government of Brazil has funded a study of PS in cancer and infectious diseases. Brazil is currently running a study of our anti-PS mAbs against Leishmania.
Money is pouring into Peregrine from a number of sources, academic, private foundational and government.
The extensive current hiring is a leading indicator that the Peregrine program is about to expand, Avid, alone, is hiring 19 new employees and has taken on expanded top management: Truc Le and Chris Eso. This tells us that something very big is happening at Avid. Avid is a production facility. Avid is growing. What is going to be produced? I think it will be a large government contract through DTRA/TMTI. This will be separate from the current $44 million dollar contract. It will be a procurement contract for a stockpile of a fully human bavi mAb to protect against viral hemorrhagic fever diseases. Bavi is a broad spectrum anti-viral that can treat the wide variety of enveloped viruses. They include many of the most dangerous diseases out there.
The hiring, especially at Avid, tells me that there is going to be a large and imminent expansion at Avid. Over the mid term expect the announcement of an early approval (EUA) of a fully human bavi mAb by DTRA/TMTI and FDA. Then expect announcement of a very large stockpile procurement order at Avid for the mAb.
I think a large procurement stockpile order to Avid will go a long way in supporting the phase 3 cancer trial(s). Peregrine has many options.
On a separate note, I, personally, have voted to support Peregrine. I own a share of this company, and I will support management going forward. It is an absolute myth that management has not performed superbly; they have made major pre-clinical and clinical progress. The major support that is coming from academia, a major private foundation and governments should inform shareholders that this is an up and coming company with transformational medical technology. Supporting your company is in your interest.
The incessant bashing from some semi-literate individuals working out of cardboard cubicles should not be heeded. It’s problematic to say, exactly, who they are, or who they are employed by, but the fact that they snipe at Peregrine all day every day tells you that they have an economic interest in suppressing the price. Their day-long efforts to instill fear and doubt to produce sellers, tells you their general motivation. Because they remain here, constantly, they’re compensated. The only sane reason to suppress a price is to buy the commodity. Roundabout, they, and their employers want to buy Peregrine. Keep that thought firmly in mind. Big Pharmas will eventually buy; they just don’t want to pay the full price. Too bad, I’m holding for the much better price.
In my opinion, long investors should support this company by voting their proxy sooner rather than later, so we can move to a new price structure that satisfies NASDAQ requirements and accommodates institutional investors that are limited to prices above certain limits. I want these investors to be able to start buying and having the price supported by their buying volume.
I would like to see Peregrine releasing the bulk of their anti-viral and anti-cancer results to a clientele that includes large investors that are not eligible to buy at these current prices.
sunstar
Here is the panel of graphs that show the deadly power of Peregrine’s anti-HIV mAb, PGN632: 11.31:
